Contribution of baicalin on the plasma protein binding displacement and CYP3A activity inhibition to the pharmacokinetic changes of nifedipine in rats in vivo and in vitro

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cheng, Zhen Yu ^a   Tian, Xin ^a   Gao, Jie ^a   Li, Hong Meng ^a   Jia, Lin Jing ^a   Qiao, Hai Ling ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALIN; CYTOCHROME P450 3A; NIFEDIPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; RAT;

ANIMALS; BLOOD PROTEINS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FLAVONOIDS; MALE; MICROSOMES, LIVER; NIFEDIPINE; PLANT EXTRACTS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84900393215     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087234     Document Type: Article

References (54)

1. Tang Y, Zhu H, Zhang Y, Huang C (2006) Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography. Biomedical Chromatography 20: 1116-1119. (Pubitemid 44697053)
2. Lindup WE, Orme MC (1981) Clinical pharmacology: plasma protein binding of drugs. British Medical Journal (Clinical Research Edition) 282: 212-214. (Pubitemid 11188579)
3. Addison RS, Parker-Scott SL, Eadie MJ, Hooper WD, Dickinson RG (2000) Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers. European Journal of Clinical Pharmacology 56: 715-721. (Pubitemid 32204495)
4. Dhillon S, Richens A (1998) Valproic acid and diazepam interaction in vivo. British Journal of Clinical Pharmacology 13: 553-560.
5. Kazuki Y, Kobayashi K, Aueviriyavit S, Oshima T, Kuroiwa Y, et al. (2013) Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Human Molecular Genetics 22: 578-592.
6. Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C (2010) Semimechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole. Clinical Pharmacokinetics 49: 53-66.
7. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR (2011) In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clinical Pharmacology and Therapeutics 90: 414-422.
8. Zamuner S, Johnson BM, Pagliarusco S, Fina P, Peroni M, et al. (2010) Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. British Journal of Clinical Pharmacology 70: 537-546.
9. Borrelli F, Izzo AA (2009) Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. The AAPS Journal 11: 710-727.
10. Yang JM, Ip SP, Xian Y, Zhao M, Lin ZX, et al. (2012) Impact of the herbal medicine Sophora flavescens on the oral pharmacokinetics of indinavir in rats: the involvement of CYP3A and P-glycoprotein. PloS One 7: e31312.
11. Gao Z, Huang K, Xu H (2001) Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacological research 43: 173-178. (Pubitemid 32601447)
12. Li L, Bao H, Wu J, Duan X, Liu B, et al. (2012) Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity. International Immunopharmacology 13: 15-22.
13. Qiao H, Han H, Hong D, Ren Z, Chen Y, et al. (2011) Protective effects of baicalin on carbon tetrachloride induced liver injury by activating PPARγ and inhibiting TGFβ1. Pharmaceutical Biology 49: 38-45.
14. Wan JY, Gong X, Zhang L, Li HZ, Zhou YF, et al. (2008) Protective effect of baicalin against lipopolysaccharide/D-galactosamine-induced liver injury in mice by up-regulation of heme oxygenase-1. European Journal of Pharmacology 587: 302-308.
15. Uchiyama Y, Tagami J, Kamisuki S, Kasai N, Oshige M, et al. (2005) Selective inhibitors of terminal deoxyribonucleotidyltransferase (TdT): baicalin and genistin. Biochimica et Biophysica Acta 1725: 298-304. (Pubitemid 41393526)
16. Wolniak M, Oszmianski J, Wawer I (2008) Solid-state NMR studies and DFT calculations of flavonoids: baicalein, baicalin and wogonoside. Magnetic Resonance in Chemistry 46: 215-225.
17. Wright JD, Boudinot FD, Ujhelyi MR (1996) Measurement and analysis of unbound drug concentrations. Clinical Pharmacokinetics 30: 445-462. (Pubitemid 26175754)
18. Liu H, Bao W, Ding H, Jang J, Zou G (2010) Binding modes of flavones to human serum albumin: insights from experimental and computational studies. The Journal of Physical Chemistry B 114: 12938-12947.
19. Li Y, Wang Q, Yao X (2010) Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways. European Journal of Pharmacology 640: 46-54.
20. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, et al. (2009) Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. European Journal of Clinical Pharmacology 65: 403-409.
21. Tian X, Cheng ZY, He J, Jia LJ, Qiao HL (2013) Concentration-dependent inhibitory effects of baicalin on the metabolism of dextromethorphan, a dual probe of CYP2D and CYP3A, in rats. Chemico-Biological Interactions 203: 522-529.
22. Tian X, Cheng ZY, Jin H, Gao J, Qiao HL (2013) Inhibitory effects of baicalin on the expression and activity of CYP3A induce the pharmacokinetic changes of midazolam in rats. Evidence-Based Complementary and Alternative Medicine 2013, http: //dx.doi.org/10.1155/2013/179643.
23. Gao N, Zou D, Qiao HL (2013) Concentration-dependent inhibitory effect of Baicalin on the plasma protein binding and metabolism of chlorzoxazone, a CYP2E1 probe substrate, in rats in vitro and in vivo. PloS One 8: e53038.
24. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2012) Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews 54: 1271-1294.
25. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology 48: 716-727. (Pubitemid 29520596)
26. Zamuner S, Johnson BM, Pagliarusco S, Fina P, Peroni M, et al. (2010) Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. British Journal of Clinical Pharmacology 70: 537-546.
27. Hoch M, Hoever P, Alessi F, Theodor R, Dingemanse J (2013) Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. European Journal of Clinical Pharmacology 69: 523-532.
28. Wang Y, Zou MJ, Zhao N, Ren JG, Zhou H, et al. (2011) Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats. Journal of Food Science 76: T30-34.
29. Gonzalez-Perez V, Connolly EA, Bridges AS, Wienkers LC, Paine MF (2012) Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. Drug Metabolism and Disposition 40: 2136-2142.
30. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL (2010) Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metabolism and Disposition 38: 981-987.
31. Reilly PE, Mason SR, Read MA (1999) Human, rat and crocodile liver microsomal monooxygenase activities measured using diazepam and nifedipine: effects of CYP3A inhibitors and relationship to immunochemically detected CYP3A apoprotein. Comparative Biochemistry and Physiology Part C 122: 197-204. (Pubitemid 29070783)
32. Lee KJ, Park HJ, Shin YH, Lee CH (2004) Effect of glycyrrhizic acid on protein binding of diltiazem, verapamil, and nifedipine. Archives of Pharmacal Research 27: 978-983. (Pubitemid 43073697)
33. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, et al. (2010) A comparison of pharmacokinetics between humans and monkeys. Drug Metabolism and Disposition 38: 308-316.
34. Poor M, Kunsagi-Mate S, Czibulya Z, Li Y, Peles-Lemli B, et al. (2012) Fluorescence spectroscopic investigation of competitive interactions between ochratoxin A and 13 drug molecules for binding to human serum albumin. Luminescence: In press.
35. Mohri K, Uesawa Y, Sagawa K (2000) Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. Drug Metabolism and Disposition 28: 482-486. (Pubitemid 30185688)
36. Guo Y, Dai J, Qian G, Guo N, Ma Z, et al. (2007) Determination of nifedipine in human plasma and its use in bioequivalence study. International Journal of Pharmaceutics 341: 91-96. (Pubitemid 47088112)
37. Zeng MF, Pan LM, Zhu HX, Zhang QC, Guo LW (2010) Comparative pharmacokinetics of baicalin in plasma after oral administration of Huang-Lian-Jie-Du-Tang or pure baicalin in MCAO and sham-operated rats. Fitoterapia 81: 490-496.
38. Litterst CL, Mimnaugh EG, Reagan RL, Gram TE (1975) Drug metabolism by microsomes from extrahepatic organs of rat and rabbit prepared by calcium aggregation. Life Sciences 17: 813-818.
39. Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Lown KS, et al. (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha, 25-dihydroxyvitamin D3. Molecular pharmacology 51: 741-754. (Pubitemid 27224679)
40. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and Pglycoprotein. Pharmaceutical Research 16: 408-414. (Pubitemid 29162099)
41. Buur JL, Baynes RE, Smith GW, Riviere JE (2009) A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition. Research in Veterinary Science 86: 293-301.
42. Choi YH, Lee MG (2012) Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes. Xenobiotica 42: 483-495.
43. Lombardo F, Obach RS, Shalaeva MY, Gao F (2002) Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. Journal of Medicinal Chemistry 45: 2867-2876. (Pubitemid 34627657)
44. Soligard HT, Nilsen OG, Bratlid D (2010) Displacement of bilirubin from albumin by ibuprofen in vitro. Pediatric Research 67: 614-618.
45. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition 17: 273-310. (Pubitemid 26176731)
46. Renwick AG, Ahsan CH, Challenor VF, Daniels R, Macklin BS, et al. (1992) The influence of posture on the pharmacokinetics of orally administered nifedipine. British Journal of Clinical Pharmacology 34: 332-336.
47. Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, et al. (2008) Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metabolism and Disposition 36: 2287-2291.
48. Lai MY, Hsiu SL, Hou YC, Tsai SY, Chao PD (2004) Significant decrease of cyclosporine bioavailability in rats caused by a decoction of the roots of Scutellaria baicalensis. Planta Medica 70: 132-137.
49. Aoki M, Okudaira K, Haga M, Nishigaki R, Hayashi M (2010) Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine. Drug Metabolism and Disposition 38: 1183-1188.
50. Grundy JS, Eliot LA, Foster RT (1997) Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharmaceutics and Drug Disposition 18: 509-522. (Pubitemid 27338982)
51. Ito K, Brown HS, Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. British Journal of Clinical Pharmacology 57: 473-486. (Pubitemid 38519653)
52. Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A (2006) Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. Journal of Pharmaceutical Sciences 95: 2778-2787. (Pubitemid 46093184)
53. Lilja JJ, Backman JT, Neuvonen PJ (2005) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. British Journal of Clinical Pharmacology 59: 433-439. (Pubitemid 40523887)
54. MacKichan JJ (1989) Protein binding drug displacement interactions fact or fiction? Clin Pharmacokinet 16: 65-73.